The acquisition will allow the firms to provide annotated biospecimens, as well as sequencing, bioinformatics, and lab services to hospitals and clinicians.
The companies will combine their respective technologies to develop mass spectrometry-based proteomics assays for adverse pregnancy outcomes.
A survey of more than 2,400 pregnant women found that their views on testing largely fell into four clusters, shaped by their thoughts on risk, ambiguity, and more.
Two new studies found that prenatal whole-exome sequencing could uncover clinically significant variants in an additional 8 to 12 percent of fetuses with structural anomalies.
The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.
A randomized clinical trial from France revealed similar miscarriage rates in women who had cell-free DNA screening for trisomy 21 prior to invasive testing.
The $375 million deal marks the integration of Myriad, a leader in the hereditary cancer genetic screening market, with Counsyl, a leader in reproductive genetic screening.
Myriad will merge Counsyl’s reproductive tests with its preventive care business unit into a new business unit called Myriad Women’s Health.
The Associated Press reports that an ethicist predicts that prenatal diagnosis and other advances will lead to more choices being available to prospective parents.
A UK team sequenced the exomes of 16 fetuses and their parents, delivering a molecular diagnosis for 13.
The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.
The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.
New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.
In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.